N-Acetyl Semax Amidate Spray — Research Grade Neuropeptide
N-Acetyl Semax Amidate Spray delivers the most potent form of the Semax peptide family in a nasal spray formulation, enabling intranasal delivery for CNS-focused research protocols. N-Acetyl Semax Amidate combines N-terminal acetylation and C-terminal amidation on the ACTH 4-10 derived heptapeptide sequence, producing enhanced enzymatic stability and extended biological activity compared to earlier Semax variants. Intranasal delivery bypasses the blood-brain barrier via the olfactory route, making this formulation particularly relevant for direct neurological research applications. HPLC verified at ≥99% purity per batch.
Research Background
Intranasal Semax has been studied extensively in Russian clinical research, with published data in ischemic stroke (significant neurological recovery score improvements), optic nerve atrophy (improved visual acuity and fields), and cognitive function models. The N-Acetyl Amidate form is the highest-potency variant, with research suggesting several-fold greater BDNF induction compared to unmodified Semax. Nasal spray delivery provides a convenient research administration route that closely mirrors the intranasal protocols used in published Russian clinical studies.
Compound Specifications
- Format: Nasal spray solution
- Purity: ≥99% (HPLC verified)
- Active compound: N-Acetyl Semax Amidate
- Storage: 2–8°C refrigerated, protected from light
- Base sequence: Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-10)
Certificate of Analysis
Third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
